In vivo (Athens, Greece) · 2014
Sodium caseinate induces increased survival in leukaemic mouse J774 model.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Córdova-Galaviz Yolanda, Ledesma-Martínez Edgar, Aguíñiga-Sánchez Itzen, Soldevila-Melgarejo Gloria, Soto-Cruz Isabel, Weiss-Steider Benny, Santiago-Osorio Edelmiro
Аннотация
BACKGROUND: Acute myeloid leukaemia is a neoplastic disease of haematopoietic stem cells. Although there have been recent advances regarding its treatment, mortality remains high. Consequently, therapeutic alternatives continue to be explored. In the present report, we present evidence that sodium caseinate (CasNa), a salt of the principal protein in milk, may possess important anti-leukaemic properties.
MATERIALS AND METHODS: J774 leukaemia macrophage-like cells were cultured with CasNa and proliferation, viability and differentiation were evaluated. These cells were also inoculated into BALB/c mice as a model of leukemia.
RESULTS: We demonstrated that CasNa inhibits the in vitro proliferation and reduces viability of J774 cells, and leads to increased survival in vivo in a leukaemic mouse model.
CONCLUSION: These data indicate that CasNa may be useful in leukaemia therapy.
MATERIALS AND METHODS: J774 leukaemia macrophage-like cells were cultured with CasNa and proliferation, viability and differentiation were evaluated. These cells were also inoculated into BALB/c mice as a model of leukemia.
RESULTS: We demonstrated that CasNa inhibits the in vitro proliferation and reduces viability of J774 cells, and leads to increased survival in vivo in a leukaemic mouse model.
CONCLUSION: These data indicate that CasNa may be useful in leukaemia therapy.